Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: Time to take stock!

Journal of Clinical Oncology

Volumn 20, Issue 6, 2002, Pages 1446-1448

  Marx, Gavin M ^a   Steer, Christopher B ^a   Harper, Peter ^a   Pavlakis, Nick ^a   Rixe, Olivier ^a   Khayat, David ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; PACLITAXEL; SEMAXANIB;

BLEEDING; CANCER; CANCER COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; HYPERTENSION; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT PLANNING; VASCULAR DISEASE; VEIN DISEASE;

EID: 0037087653     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.6.1446     Document Type: Editorial

References (21)

1. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors
2. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
3. The role of the coagulation system in tumour angiogenesis
4. Monoclonal antibodies angiogenesis
5. SU5416, a molecularly targeted novel antiangiogenesis drug: Clinical pharmacokinetics and safety review
6. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer
7. Phase I/II study of SU5416 in combination with irinotecan/5-FU/LV (IFL) in patients with metastatic colorectal cancer
8. A phase I/II trial and pharmacokinetic study of SU5416 in combination with paclitaxel/carboplatin
9. Cisplatin triggers platelet activation
10. Severe vascular toxicity associated with cisplatin-based chemotherapy
11. Redefining the target: Chemotherapeutics as antiangiogenics
12. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: A phase II multicenter trial
13. Anti-angiogenic agents: Clinical trial design and therapies in development
14. A pilot trial demonstrates the safety of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC)
15. P1-88 demonstrates dose-dependent inhibition of tumour growth in the BC1 syngeneic rat mammary adenocarcinoma
16. The heparanase inhibitor P1-88 reduces tumour growth in two rat mammary adenocarcinoma models, demonstrating schedule dependency and possible synergy with cisplatin
17. Clinical trials of antiangiogenic drags: Opportunities, problems, and assessment of initial results
18. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents
19. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma
20. Clinical trial designs for cytostatic agents: Are new approaches needed?
21. There are no bad anticancer agents, only bad clinical trial designs: Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture